Assessment of prognostic factors in previously treated Japanese patients with metastatic renal cell carcinoma who received nivolumab: An observational multi‑institute study

Ito,Toshiki; Mizutani,Kosuke; Takahara,Kiyoshi; Ando,Ryosuke; Yasui,Takahiro; Shiroki,Ryoichi; Koie,Takuya; Miyake,Hideaki

doi:10.3892/mco.2021.2446

Assessment of prognostic factors in previously treated Japanese patients with metastatic renal cell carcinoma who received nivolumab: An observational multi‑institute study

Authors:
- Toshiki Ito
- Kosuke Mizutani
- Kiyoshi Takahara
- Ryosuke Ando
- Takahiro Yasui
- Ryoichi Shiroki
- Takuya Koie
- Hideaki Miyake
View Affiliations

Affiliations: Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431‑3192, Japan, Department of Urology, Gifu University Graduate School of Medicine, Gifu 501‑1194, Japan, Department of Urology, Fujita Health University School of Medicine, Toyoake, Aichi 470‑1192, Japan, Department of Nephro‑urology, Nagoya City University Graduate School of Medical Science, Nagoya, Aichi 467‑8601, Japan
Published online on: November 21, 2021 https://doi.org/10.3892/mco.2021.2446
Article Number: 17

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the prognosis of Japanese patients with metastatic renal cell carcinoma (mRCC) receiving nivolumab and to identify factors predicting the overall survival (OS) in this cohort of patients. This study retrospectively assessed the outcomes of 77 consecutive Japanese patients with mRCC who were treated using either 1 or 2 molecular‑targeted agents followed by nivolumab in routine clinical practice. The best responses to nivolumab observed were as follows: Complete response in 3 patients, partial response in 27, stable disease in 33 and progressive disease in 14; therefore, the objective response rate in the 77 patients was 39.0%. During the median follow‑up period of 11 months after the introduction of nivolumab, the median progression‑free survival and OS were 7 months and not reached, respectively. On multivariate analysis of several parameters, age, Karnofsky Performance Status (KPS) and neutrophil counts were demonstrated to be independently associated with OS in the 77 patients. By dividing these patients into 3 groups according to 3 risk factors, it was possible to stratify the OS; however, the International Metastatic Renal Cell Carcinoma Database Consortium model was unable to classify the OS. These results suggested that age, KPS and neutrophil counts were useful predictors of OS in previously treated patients with mRCC who received nivolumab.

View Figures

View References

1	Bedke J, Gauler T, Grünwald V, Hegele A, Herrmann E, Hinz S, Janssen J, Schmitz S, Schostak M, Tesch H, et al: Systemic therapy in metastatic renal cell carcinoma. World J Urol. 35:179–188. 2017.PubMed/NCBI View Article : Google Scholar
2	Flippot R, Escudier B and Albiges L: Immune checkpoint inhibitors: Toward new paradigms in renal cell carcinoma. Drugs. 78:1443–1457. 2018.PubMed/NCBI View Article : Google Scholar
3	Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015.PubMed/NCBI View Article : Google Scholar
4	Motzer RJ, Tannir NM, McDermott DF, Frontera OA, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, et al: Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 378:1277–1290. 2018.PubMed/NCBI View Article : Google Scholar
5	Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, et al: Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 380:1116–1127. 2019.PubMed/NCBI View Article : Google Scholar
6	Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, et al: Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 380:1103–1115. 2019.PubMed/NCBI View Article : Google Scholar
7	Motzer RJ, Bacik J, Murphy BA, Russo P and Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 20:289–296. 2002.PubMed/NCBI View Article : Google Scholar
8	Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol. 27:5794–5799. 2009.PubMed/NCBI View Article : Google Scholar
9	Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S and Mazumdar M: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 22:454–463. 2004.PubMed/NCBI View Article : Google Scholar
10	Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, et al: The international metastatic renal cell carcinoma database consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: A population-based study. Lancet Oncol. 16:293–300. 2015.PubMed/NCBI View Article : Google Scholar
11	Suzuki K, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y and Fujisawa M: C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. Int J Clin Oncol. 25:135–144. 2020.PubMed/NCBI View Article : Google Scholar
12	Martini DJ, Liu Y, Shabto JM, Carthon BC, Hitron EE, Russler GA, Caulfield S, Kissick HT, Harris WB, Kucuk O, et al: Novel risk scoring system for patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Oncologist. 25:e484–e491. 2020.PubMed/NCBI View Article : Google Scholar
13	De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli P, et al: Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab. Clin Cancer Res. 25:3839–3846. 2019.PubMed/NCBI View Article : Google Scholar
14	Raimondi A, Sepe P, Zattarin E, Mennitto A, Stellato M, Claps M, Guadalupi V, Verzoni E, de Braud F and Procopio G: Predictive biomarkers of response to immunotherapy in metastatic renal cell cancer. Front Oncol. 10(1644)2020.PubMed/NCBI View Article : Google Scholar
15	Ishihara H, Tachibana H, Takagi T, Kondo T, Fukuda H, Yoshida K, Iizuka J, Kobayashi H, Okumi M, Ishida H and Tanabe K: Predictive impact of peripheral blood markers and C-reactive protein in nivolumab therapy for metastatic renal cell carcinoma. Target Oncol. 14:453–463. 2019.PubMed/NCBI View Article : Google Scholar
16	Perrone F, Minari R, Bersanelli M, Bordi P, Tiseo M, Favari E, Sabato R and Buti S: The prognostic role of high blood cholesterol in advanced cancer patients treated with immune checkpoint inhibitors. J Immunother. 43:196–203. 2020.PubMed/NCBI View Article : Google Scholar
17	Bruce-Chwatt LJ: Declaration of Helsinki. Recommendations guiding doctors in clinical research. WHO Chron. 19:31–32. 1965.PubMed/NCBI
18	Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, Zhang X, Wang WM, Qiu SJ, Zhou J and Fan J: Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 20:6212–6222. 2014.PubMed/NCBI View Article : Google Scholar
19	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.PubMed/NCBI View Article : Google Scholar
20	R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/. Accessed June 14, 2020.
21	Hinata N, Yonese J, Masui S, Nakai Y, Shirotake S, Tatsugami K, Inamoto T, Nozawa M, Ueda K, Etsunaga T, et al: A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: Interim analysis of Japanese real-world data. Int J Clin Oncol. 25:1533–1542. 2020.PubMed/NCBI View Article : Google Scholar
22	Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Kimura G, Yonese J, Yao M, et al: Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. Jpn J Clin Oncol. 47:639–646. 2017.PubMed/NCBI View Article : Google Scholar
23	Yip SM, Wells C, Moreira R, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, et al: Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium. Cancer. 124:3677–3683. 2018.PubMed/NCBI View Article : Google Scholar
24	Tamura K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A and Miyake H: Feasibility of the ACL (albumin, C-reactive protein and lactate dehydrogenase) model as a novel prognostic tool in patients with metastatic renal cell carcinoma previously receiving first-line targeted therapy. Urol Oncol. 38:6.e9–6.e16. 2020.PubMed/NCBI View Article : Google Scholar